Men's Health News

RSS

Pros and cons of weight loss surgery in men and women

Women who underwent gastric band surgery to lose weight reported significant improvements in urinary function and quality of life after the operation, according to research published in the January issue of the urology journal BJUI.

6 Jan 2011

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

People with melanoma, ovarian cancer, or prostate cancer now have a new resource that provides them with the same credible information their physicians use when determining treatment options. The National Comprehensive Cancer Network announces three new additions to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

6 Jan 2011

Physical activity associated with lower risk of death for prostate cancer patients: Study

A new study of men with prostate cancer finds that physical activity is associated with a lower risk of overall mortality and of death due to prostate cancer. The Harvard School of Public Health and University of California, San Francisco researchers also found that men who did more vigorous activity had the lowest risk of dying from the disease.

6 Jan 2011

Americans unaware of what they eat

A recent poll has found that 90% Americans say their diet is healthy but only a quarter limit the amount of fat or sugar they eat, and two-thirds do not eat enough fruit and vegetables.

5 Jan 2011

Defect in conversion of hair follicle stem cells to progenitor cells linked to male-pattern baldness

Androgenetic alopecia (AGA) is a frequent form of hair loss in both men and women. However, it is more common in men, in whom it is also known as male-pattern baldness.

5 Jan 2011

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Men are more willing to receive human papillomavirus vaccine when they learn the vaccine can prevent cancer, according to a recent University of North Carolina at Chapel Hill study.

5 Jan 2011

Elis granted exclusive rights to market Apricus Bio's Vitaros in the Gulf and part of the Middle East

Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.

5 Jan 2011

Study: Stem cells play an unexpected role in male pattern balding

Given the amount of angst over male pattern balding, surprisingly little is known about its cause at the cellular level. In a new study, published in the Journal of Clinical Investigation, a team led by George Cotsarelis, MD, chair of the Department of Dermatology at the University of Pennsylvania School of Medicine, has found that stem cells play an unexpected role in explaining what happens in bald scalp.

5 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

Encouraging results from exon skipping gene-based therapy study for DMD

Scientists at Royal Holloway, University of London have reported encouraging results in a new gene-based therapy for Duchenne Muscular dystrophy (DMD) which at present has no known cure and affects one in 3,000 young boys.

4 Jan 2011

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

Repros Therapeutics Inc. today reported it has received Institutional Review Board (IRB) approval to commence the Phase IIb study of Androxal® in men with secondary hypogonadism. The Company has submitted the protocol for FDA comment and plans to begin enrolling subjects in January. Depending on the rate of subject enrollment, Repros hopes to have the study completed before the end of 2011.

3 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Dana Farber/Harvard Cancer Center will launch a new multi-million dollar grant award program focused on prostate cancer research. It will be administered in collaboration with the Prostate Cancer Foundation.

28 Dec 2010

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Men above age 75 with high-risk prostate cancer often under-treated

Older men with high-risk prostate cancer frequently are offered fewer - and less effective - choices of treatment than younger men, potentially resulting in earlier deaths, according to a new UCSF study.

22 Dec 2010

Wyden's cancer treatment highlights debate over health care cost vs. personal choice

Sen. Ron Wyden had surgery for prostate cancer Monday, putting himself — through no fault of his own — in the middle of a debate about diagnosis, treatment and bending the cost curve.

22 Dec 2010

Mums urged not to delay births for leave scheme

Many Australian couples are delaying having a baby in order to access the federal government’s paid parental leave scheme. The scheme begins at the start of the New Year and allows eligible parents to access up to 18 weeks pay at the minimum wage. Figures show that from January 1, 2011 an estimated 148,000 families will be eligible to receive a payment of $570 a week before tax, or $10,260 over 18 weeks.

20 Dec 2010

U of A student wins annual master's thesis competition for research on light-sensitive drug for prostate cancer

The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.

20 Dec 2010

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called "monensin" prevents the growth of prostate cancer cells. Monensin is used in the meat and dairy industry, for example.

20 Dec 2010

New study suggests PSA test effective for men with prostate cancer

The PSA screening test for prostate cancer is not perfect. It can indicate cancer when none is present and miss life-threatening tumors. But a new study suggests the test is more reliable in men taking dutasteride (Avodart®), a drug widely prescribed to shrink an enlarged prostate gland.

17 Dec 2010

Men's Health News

Pros and cons of weight loss surgery in men and women

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

Physical activity associated with lower risk of death for prostate cancer patients: Study

Americans unaware of what they eat

Defect in conversion of hair follicle stem cells to progenitor cells linked to male-pattern baldness

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Elis granted exclusive rights to market Apricus Bio's Vitaros in the Gulf and part of the Middle East

Study: Stem cells play an unexpected role in male pattern balding

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Encouraging results from exon skipping gene-based therapy study for DMD

Repros receives IRB approval for Androxal Phase IIb study in secondary hypogonadism

FDA approves Endo's FORTESTA Gel for low testosterone

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Men above age 75 with high-risk prostate cancer often under-treated

Wyden's cancer treatment highlights debate over health care cost vs. personal choice

Mums urged not to delay births for leave scheme

U of A student wins annual master's thesis competition for research on light-sensitive drug for prostate cancer

Researchers demonstrate that monensin antibiotic prevents prostate cancer cell growth

New study suggests PSA test effective for men with prostate cancer

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News